Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
    Meeting Abstract

    Orloff, M.; Watkins, C.; Carvajal, R. D.; Shoushtari, A. N.; Sacco, J. J.; Schlaak, M.; Gama, J.; Butler, M. O.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
    Meeting Abstract

    Huang, R.; Youssef, G.; Nelson, T.; Wen, P.; Forsyth, P.; Hodi, F. S.; Margolin, K. A.; Algazi, A. P.; Hamid, O.; Lao, C. D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
    Meeting Abstract

    Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
    Meeting Abstract

    Heredia, J. B.; Diplas, B. H.; El Nahhas, O. S. M.; Selenica, P.; Pareja, F.; Mandelker, D.; Weigelt, B.; Riaz, N.; Rosen, E.; Sfeir, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
    Meeting Abstract

    McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
    Meeting Abstract

    Burton, E.; Milton, D.; Simpson, L.; Tetzlaff, M.; Glitza, I. C.; Ross, M. I.; Gershenwald, J. E.; McQuade, J.; Wong, M.; Patel, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
    Meeting Abstract

    Ku, G.; Shen, L.; Klempner, S. J.; Pan, H.; Kratz, J.; Liang, X.; Deng, Y.; Kim, S.; Wang, Z.; Feller, L.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
    Meeting Abstract

    Rodon, J.; Chaney, M. F.; Cohen, J.; Garyantes, T. K.; Ishizuka, J.; Lin, J. J.; Lorusso, P.; Mita, A.; Mita, M.; Muller, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
    Meeting Abstract

    Ferrarotto, R.; Bobbili, P.; Bowles, D. W.; Even, C.; Gordon, G.; Gutierrez, A.; Metcalf, R.; Muzaffar, J.; Nguyen, C.; Oliva, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
    Meeting Abstract

    Nabell, L.; Ho, A. L.; Posner, M. R.; Neupane, P.; Naqash, A. R.; Wong, S.; Niu, J. J.; Pearson, A. T.; Laux, D.; Adkins, D. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save